Clinical Trials Browser

Phase 1/2 × INDUSTRY × fludarabine phosphate × Clear all

NCT05589896 2026-02-24

A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies

Phase 1/2 Recruiting

Classical hematologyDermatologicLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hematologic Diseases, Hodgkin Disease, Leukemia, Lymphoma, Leukemia, B-Cell, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Cutaneous, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05566223 2026-02-23

CheckCell-2

Phase 1/2 Withdrawn

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT06009107 2025-08-08

B-ALL

Phase 1/2 Withdrawn

Burkitt Lymphoma

NCT03754933 2025-03-27

Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer

Phase 1/2 Completed

10 enrolled 22 charts

Squamous Cell Carcinoma of Head and Neck, Adenoviridae Infections, Head and Neck Neoplasms

NCT05207722 2024-12-12

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Phase 1/2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT04109482 2024-07-22

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Phase 1/2 Terminated

Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT02400281 2024-07-03

Study of Crenolanib Combined With Chemotherapy in FLT3-mutated Acute Myeloid Leukemia Patients

Phase 1/2 Completed

28 enrolled 15 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02626338 2023-12-20

Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

Phase 1/2 Completed

16 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03778619 2020-07-28

MG4101 Plus Rituximab Including Lymphodepletion in Patient With r/r NHL B-cell Origin

Phase 1/2 Unknown

Lymphoma, Non-Hodgkin